Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atazanvir/ritonavir+ efavirenz · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Atazanvir/ritonavir + efavirenz | DRUG | Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks. |
Inclusion Criteria: * Provide written informed consent * HIV positive with plasma HIV RNA viral load of ≥ 1000 copies/mL and CD4 cell count of ≥ 50 cells/mm3 * Antiretroviral (ARV) naive prior to enrollment * Normal plasma triglycerides ≤ 200 mg/dL * Women of child-bearing age must use effective ba...
Top 20 of 28 competitors
Atazanavir/ritonavir + efavirenz is used for the treatment of HIV infections. It is a combination regimen being studied as a nucleoside-sparing approach, meaning it avoids the use of nucleoside reverse transcriptase inhibitors. The drug is currently in Phase 3 clinical development for this indication.
Atazanavir/ritonavir + efavirenz is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate this combination regimen for the treatment of HIV infections.
Atazanavir/ritonavir + efavirenz is in Phase 3 clinical development. It is an investigational combination regimen for HIV infections and has not been approved by regulatory authorities. One Phase 3 trial has been completed to evaluate its safety and efficacy.
Atazanavir/ritonavir + efavirenz has one completed Phase 3 trial, NCT00135343, titled "A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen." This trial enrolled 60 participants with HIV infections in the United States and was a randomized, controlled study.
Atazanavir/ritonavir + efavirenz is a combination regimen that includes the drugs atazanavir, ritonavir, and efavirenz. It is being studied as a single treatment approach for HIV infections, combining these three antiretroviral agents to provide a nucleoside-sparing option.